A Study of Sugammadex versus a Placebo for Prevention of Residual Neuromuscular Block

Overview

About this study

The purpose of this study is to determine whether patients who receive sugammadex immediately after the removal of a surgical breathing tube will have a decrease in the incidence of postoperative residual paralysis and an associated decrease in the incidence of postoperative respiratory depression.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Patients undergoing surgery with general anesthesia
  • Patients weighing ≥ 80 pounds
  • Patients not intubated prior to surgery
  • Patients who are able to give informed consent

Exclusion Criteria

  • Patients unable to give informed consent
  • Patients whose condition will not allow for placement of the electrode PadSet of ExSpiron
  • Patients who are anticipated to remain intubated in recovery period

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Johnathan Renew, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions